share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144：擬議出售證券
美股sec公告 ·  05/03 03:35
牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,783 shares of common stock on 05/02/2024, as per the latest filing. The shares, valued at an aggregate market value of $120,432, were acquired through a restricted stock vest on 05/01/2024. This transaction follows a recent history of sales by Watanabe over the past three months, totaling 17,368 shares for gross proceeds of $191,868.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,783 shares of common stock on 05/02/2024, as per the latest filing. The shares, valued at an aggregate market value of $120,432, were acquired through a restricted stock vest on 05/01/2024. This transaction follows a recent history of sales by Watanabe over the past three months, totaling 17,368 shares for gross proceeds of $191,868.
根據最新文件，Arcutis Biotherapeutics, Inc.高管渡邊託德·富蘭克林定於2024年2月5日出售13,783股普通股。這些股票的總市值爲120,432美元，於2024年1月5日通過限制性股票背心收購。該交易遵循了渡邊在過去三個月中的近期銷售記錄，共計17,368股股票，總收益爲191,868美元。
根據最新文件，Arcutis Biotherapeutics, Inc.高管渡邊託德·富蘭克林定於2024年2月5日出售13,783股普通股。這些股票的總市值爲120,432美元，於2024年1月5日通過限制性股票背心收購。該交易遵循了渡邊在過去三個月中的近期銷售記錄，共計17,368股股票，總收益爲191,868美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。